It has also been reported that suppression of PI3K‐AKT‐mTOR pathway was enhanced by combined targeting of EGFR and CK2 in lung cancer models relying on EGFR activity (Bliesath et al, 2012). This evidence concerns the gene PIK3CG and lung carcinoma.